rs7202877 — CTRB1

Intergenic variant near CTRB1/CTRB2 that regulates chymotrypsinogen expression and GLP-1-stimulated insulin secretion; T allele carriers have mildly impaired incretin-driven beta-cell response and modestly elevated type 2 diabetes risk

See your personal result for CTRB1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Gut Enzyme That Shapes Your Insulin Response

Every time you eat, your small intestine releases hormones called incretins — principally GLP-111 GLP-1
glucagon-like peptide-1: a gut hormone that amplifies insulin secretion from the pancreas in response to a meal — that tell your pancreatic beta cells to release insulin in proportion to the meal's size. This variant near the CTRB1 and CTRB2 genes determines how efficiently that signal reaches your beta cells, with measurable consequences for both type 2 diabetes risk and how well DPP-4 inhibitor medications work for you.

The Mechanism

CTRB1 and CTRB2 encode chymotrypsinogen22 chymotrypsinogen
the inactive precursor of chymotrypsin, one of the most abundant digestive proteases in the small intestine, which is activated in the gut lumen to cleave dietary proteins. rs7202877 sits in an intergenic region between BCAR1 and the CTRB1/CTRB2 cluster on chromosome 16 and acts as an [expression quantitative trait locus (eQTL) | a DNA variant that controls how much of a nearby gene's mRNA is produced, without changing the protein sequence itself] for both CTRB1 and CTRB2. The G allele increases CTRB1 and CTRB2 expression, raising fecal chymotrypsin activity. This elevated chymotrypsin activity appears to enhance beta-cell sensitivity to GLP-1 signaling — the precise molecular link is not yet fully resolved, but the pharmacological consequence is clear.

The Evidence

The landmark 2013 study33 landmark 2013 study
't Hart et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes, 2013 by 't Hart et al. in nondiabetic Caucasian individuals and treated T2D cohorts demonstrated that rs7202877 produces a 30–40% difference in GLP-1-stimulated insulin secretion between genotype groups. In a separate cohort of 527 T2D patients on DPP-4 inhibitors, G-allele carriers achieved an absolute 0.51 ± 0.16% (5.6 ± 1.7 mmol/mol) smaller reduction in HbA1c compared to T homozygotes — yet showed no difference in response to GLP-1 receptor agonists such as liraglutide. This treatment paradox reflects the same biology: G-allele carriers already benefit from enhanced endogenous incretin sensitivity and have less remaining incretin-pathway reserve to capture with a DPP-4 inhibitor.

Harder et al. (J Clin Endocrinol Metab, 2013)44 Harder et al. (J Clin Endocrinol Metab, 2013)
Harder MN et al. Type 2 diabetes risk alleles near BCAR1 and in ANK1 associate with decreased β-cell function whereas risk alleles near ANKRD55 and GRB14 associate with decreased insulin sensitivity. J Clin Endocrinol Metab, 2013 studied 5,739 Danish individuals and confirmed the T-allele mechanism: carriers had a significantly decreased disposition index55 disposition index
a measure of pancreatic beta-cell compensatory capacity that accounts for both insulin sensitivity and insulin secretion (p = 0.02), locating the diabetogenic effect squarely in beta-cell function rather than in peripheral insulin resistance.

A case-control replication in 1,961 Chinese Han participants (Kazakova et al., Acta Biochim Pol, 2018)66 1,961 Chinese Han participants (Kazakova et al., Acta Biochim Pol, 2018)
Kazakova EV et al. Association between RBMS1 gene rs7593730 and BCAR1 gene rs7202877 and type 2 diabetes mellitus in the Chinese Han population. Acta Biochim Pol, 2018 found GG homozygotes had a dramatically lower T2DM risk compared to TT carriers (OR 0.44, 95% CI 0.20–0.96, p = 0.038), with the G allele also correlating with lower total cholesterol and LDL-C levels.

Practical Actions

For the approximately 76% of people with the TT genotype, this variant has no special dietary or supplement implication — it represents the population baseline. Where it matters most is for people already prescribed or considering a DPP-4 inhibitor: TT carriers tend to respond better to these drugs, while G carriers may benefit more from alternative incretin-pathway approaches such as GLP-1 receptor agonists. If you have T2D or prediabetes and are a G allele carrier, discuss with your prescriber whether a GLP-1 receptor agonist rather than a DPP-4 inhibitor is a better fit for your pharmacogenetics.

Interactions

This variant acts in the same incretin pathway as TCF7L2 rs7903146 (the strongest common genetic predictor of T2D) and KCNJ11 rs5219 (a beta-cell ATP-sensitive potassium channel variant). Carriers of risk alleles at multiple beta-cell loci accumulate additive deficits in insulin secretion capacity. The CTRB1/2 pathway is distinct from TCF7L2's Wnt-mediated transcription and from KCNJ11's ion channel mechanism, meaning all three can independently compound. See compound action proposals in harvesting notes.

Drug Interactions

sitagliptin reduced_efficacy literature
saxagliptin reduced_efficacy literature
linagliptin reduced_efficacy literature
alogliptin reduced_efficacy literature

Nutrient Interactions

dietary protein altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

TT Baseline Incretin Response Normal

Common genotype — standard incretin-driven insulin secretion

CTRB1 and CTRB2 are expressed primarily in the exocrine pancreas and small intestine. The rs7202877 T allele is associated with lower CTRB1/CTRB2 expression compared to the G allele, meaning slightly less chymotrypsin activity. In absolute terms this is the baseline — the majority of the world population carries this genotype and it defines the typical incretin response. The mild attenuation in GLP-1-stimulated insulin secretion associated with the T allele is a population-level average effect, not a discrete impairment.

From a pharmacogenomic standpoint, TT is the preferred genotype for DPP-4 inhibitor therapy: DPP-4 inhibitors prevent breakdown of endogenous GLP-1, and TT carriers have more incretin pathway capacity to preserve.

GG Strongest Incretin Advantage Beneficial

Two G alleles — highest chymotrypsin activity and lowest T2D risk from this locus

The GG genotype represents the maximum expression of CTRB1/CTRB2 from this locus. The 30–40% improvement in GLP-1-stimulated insulin secretion shown in the 't Hart 2013 study was most pronounced in G-allele carriers. The protective effect observed in the Chinese Han cohort (OR 0.44 for GG vs TT) is one of the larger protective effects seen for a common variant at a metabolic locus. The concurrent finding of lower LDL-C in G carriers in that cohort raises the possibility of secondary lipid-pathway effects, though the mechanism is not yet established.

Because DPP-4 inhibitors work by preventing GLP-1 degradation (raising endogenous GLP-1 levels), GG carriers — who already respond robustly to whatever GLP-1 is present — derive less incremental benefit from the drug. GLP-1 receptor agonists, which act directly on the receptor independently of endogenous GLP-1 levels, are not expected to show this genotype-driven attenuation.

GT Enhanced Incretin Sensitivity Intermediate

One G allele — moderately enhanced chymotrypsin activity and GLP-1 response

The 't Hart 2013 study demonstrated a 30–40% difference in GLP-1-stimulated insulin secretion between genotype groups. As a heterozygote you capture roughly half of this advantage versus TT. The Kazakova 2018 Chinese cohort showed that even heterozygous GT carriers had reduced T2DM risk under the recessive model (GG vs GT+TT: OR 0.67), suggesting some dose-dependent protection at the heterozygous level.

For prescribed DPP-4 inhibitors, the reduced HbA1c effect (average −0.51% in G carriers overall) means your prescriber may consider alternative or complementary agents if glycaemic targets are not met on a gliptin alone.